Specialty Pharma Underperforms S&P 500 For First Time Since 2009
As the year winds down, good riddance might be a popular sentiment for specialty pharma, which underperformed against the S&P 500 for the first time since 2009 as Martin Shkreli, Epipen "gauging" and Valeant "scandal" stories took their toll. But the theme for 2017 might not be a whole lot better. Try uncertainty.
Also see
Livermore Partners Huge Gain On Valeant . . .
SORRY! This content is exclusively for paying members. If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.
|
